Sigma-Aldrich Acquires Cell Marque
Sigma-Aldrich has reached an acquisition agreement with Cell Marque to further their antibody portfolio.
Sigma-Aldrich announced on Oct. 3, 2014, that it had agreed to acquire Cell Marque, a company focused on producing and marketing antibodies for diagnostic immunohistochemistry, for an undisclosed price. The acquisition will strengthen Sigma-Aldrich’s antibody portfolio.
"We expect that Cell Marque's strong in vitro diagnostic antibody product lines and solid relationships with pathologists and companies that provide automated staining instrumentation will broaden the diagnostic health reach of Sigma-Aldrich," Frank Wicks, PhD, president of Sigma-Aldrich's Applied Business Unit, said in a press release.
Source: Sigma-Aldrich
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
